• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Targeted therapies in metastatic gastric cancer: Current knowledge and future perspective

    2019-10-28 09:17:50AntonioPellinoErikaRielloFlorianaNappoStefanoBrignolaSabinaMurgioniSelmaAhceneDjaballahSaraLonardiVittorinaZagonelMassimoRuggeFotiosLoupakisMatteoFassan
    World Journal of Gastroenterology 2019年38期

    Antonio Pellino, Erika Riello, Floriana Nappo, Stefano Brignola, Sabina Murgioni, Selma Ahcene Djaballah,Sara Lonardi, Vittorina Zagonel, Massimo Rugge, Fotios Loupakis, Matteo Fassan

    Abstract Gastric cancer (GC) represents a leading cause of cancer related morbidity and mortality worldwide accounting for more than 1 million of newly diagnosed cases and thousands of deaths every year. In the last decade, the development of targeted therapies and the optimization of already available chemotherapeutic drugs has expanded the available treatment options for advanced GC and granted better survival expectations to the patients. At the same time, global efforts have been undertaken to investigate in detail the genomic and epigenomic heterogeneity of this disease, resulting in the identification of new specific and sensitive predictive and prognostic biomarkers and in innovative molecular classifications based on gene expression profiling. Nonetheless, several randomized studies aimed at exploring new innovative agents, such as immune checkpoint inhibitors, failed to demonstrate clinically meaningful survival advantages. Therefore, it is essential to further improve the molecular characterization of GC subgroups in order to provide researchers and medical oncologists with new tools for patients' selection and stratification in future clinical development programs and subsequent trials. The aim of the present manuscript is to provide a global overview of the recent molecular classifications from The Cancer Genome Atlas and the Asian Cancer Research Group and to present key promising developments in the field of immunotherapy and targeted therapies in metastatic GC.

    Key words: Gastric cancer; Personalized medicine; Predictive biomarkers; Molecular diagnostic; The Cancer Genome Atlas; Asian Cancer Research Group

    INTRODUCTION

    Gastric Cancer (GC) is the third leading cause of cancer death and the fifth most common malignancy worldwide for both sex, accounting for over 1 million new diagnoses and almost 800000 patients deaths in 2018[1]. Over 70% of GCs occur in low/middle income countries with the highest rates in Eastern Asia, Eastern Europe and South America and the lowest rates in North America and Western European countries[2,3].

    Since the middle of the 20thcentury a progressive decline of distal GC incidence has been observed, possibly due to recognition and eradication of certain risk factors such as Helicobacter pylori (H. pylori), the introduction of refrigerators and an increased use of fresh food[4,5]. Conversely, the rate of gastroesophageal junction cancer (GEJC) is increasing in Western countries, which probably reflects the increase of gastroesophageal reflux disease and visceral obesity[6,7]. Considering the rising of worldwide population, the absolute number of new diagnoses per year is increasing,so that GC still remains an important cause of cancer-related mortality and a main global health-care problem.

    Surgery is the only potentially curative treatment while neoadjuvant and adjuvant therapies should be integrated with surgery in locally advanced disease. Despite these multimodal treatments the 5 years overall survival is less than 30%, and in metastatic setting the prognosis remains poor with a median overall survival (OS) of 1 year[8].

    The last decade has been characterized by a better understanding of molecular mechanisms of pathogenesis and biology of GC with the definition of new genomic classifications and identification of prognostic and predictive biomarkers potentially predictive of response to innovative target agents. Despite this, up to now, few targetdirected options have been approved for metastatic GC. The anti-human epidermal growth factor receptor-2 (HER2) drug trastuzumab has been the first target agent approved for HER2 high expressing advanced GCs and GEJCs, while the antiangiogenic drug ramucirumab has received approval in the second-line setting as a monotherapy or in combination with paclitaxel. More recently, anti-PD1 agents such as nivolumab and pembrolizumab have been approved for patient with heavily pretreated advanced GC in some Asian countries and North America, respectively.

    More than 90 percent of GCs are adenocarcinomas. According to Lauren's criteria,gastric adenocarcinomas are divided into intestinal (54%), diffuse (32%), and indeterminate type (15%), which present distinct epidemiology, histological appearance, cell differentiation and molecular pathogenesis[9,10]. Intestinal carcinomas are more likely to be sporadic than inherited and causally related to H. pylori infection and the Correa's phenotypic multistep cascade (i.e., longstanding gastritis, atrophic gastritis, dysplasia and adenocarcinoma)[11]. Histologically, diffuse-type adenocarcinomas are poorly differentiated and composed by discohesive cells usually characterized by with a dysregulation in the expression of E-cadherin, a key cell surface and connection protein[12]. Both Lauren classification and the World Health Organization (WHO) 2010 classification[13], although widely used in the clinical practice, remain insufficient to guide precision treatments for the individual patient and GC histotype is not a parameter considered in the treatment decision process.

    GC MOLECULAR CLASSIFICATION

    The Cancer Genome Atlas research group

    In 2014, the The Cancer Genome Atlas (TCGA) network proposed a comprehensive molecular analyses of 295 primary GC based on array-based somatic copy number analyses, whole exome and genome sequencing, messenger RNA and microRNA sequencing, and reverse-phase protein array profiling. As a result, four GC subgroups were identified: Epstein-Barr (EBV) positive tumors, tumors with microsatellite instability (MSI), genomically stable tumours (GS) and tumors with chromosomal instability (CIN)[14].

    EBV activation was found in about 9% of tumor samples. All EBV positive tumours were associated to extreme DNA hypermethylation with high levels of CIMP (i.e.,CpG island methylation) of CDKN2A (p16 NK4A) promoter but not of MutL homolog 1(MLH1), characteristic of MSI associated CIMP. As previously reported, phoshatidylinositol-4-5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) mutations were detected in 80% of EBV-positive GC[15,16]. Moreover, the finding of an overexpression of programmed death ligands 1 and 2 (PD-L1 and PD-L2) and of a significant immune cell presence supported the rationale to evaluate checkpoint inhibitors in this GC subgroup.

    The MSI group (22%) was characterized by loss of mismatch repair functions which lead to alterations in length of repetitive regions in DNA known as microsatellites.The hypermethylation of MLH1 promoter region was the most representative mismatch repair defect in patient with MSI sporadic GCs. Alterations of PIK3CA,ERBB3 and ERB22 were found and in contrast to MSI colorectal cancers, BRAF mutations have never been described in MSI-GCs. MSI GCs can be part of the spectrum of inherited malignancies such as Lynch syndrome and nonpolyposis colorectal cancer syndrome which are associated to inherited germline mismatch repair defects[17]. Although colorectal and endometrial cancers are the most common cancer associated to these syndromes, other extracolic tumours including GC, can occur[18]. MSI GCs are mainly associated with intestinal histotype, are localized in the antrum, with less frequent lymph-node involvement, occur mainly in elderly age and have a more favourable prognosis[19,20].

    GS tumors (20%) are characterized by low copy number alterations and a low mutation rate. ARID1, RHOA and CDH1 mutations are the principal somatic genomic alterations observed in this class. An interchromosomal translocation between CLDN18 and ARHGAP26, mutually exclusive from RHOA mutations, was found in the 15% of GS GCs. These tumors usually occur in younger patients (median age 59),and are correlated with diffuse histology and distal localization. GS subtype was associated with the worst OS and prognosis among the four TCGA subtypes.

    The fourth TCGA group are GCs with CIN (50%) characterized by DNA aneuploidy, highly variable chromosomal copy numbers, and mutations of the tumor suppressor TP53, which is responsible for chromosomal instability. Frequent genomic amplifications of receptor tyrosine kinases (RTKs)/RAS pathway were found,including epidermal growth factor receptor (EGFR), ERBB2, ERBB3, MET proto-oncogene(MET), fibroblast growth factor receptor 2 (FGFR2), vascular endothelial growth factor A(VEGFA), and KRAS. Most of CIN GCs are classified as intestinal-type, frequently located at the gastroephageal junction/cardia[21,22].

    The Asian Cancer Research Group

    In 2015 the Asian Cancer Research Group (ACRG) proposed a different molecular classification based on gene expression profiling, genome-wide copy number microarrays and targeted gene sequencing of 300 primary tumors with the definition of four molecular subtypes: Microsatellite unstable type, epithelial to mesenchymallike type (MSS/EMT), MSS/TP53 and MSS/TP53 negative subtypes[23]. Each of these molecular subtypes was correlated to distinct clinical phenotypes and genomic alterations.

    MSI GCs occurred preferentially in the antrum, with intestinal histology (more than 60%) and half of them were diagnosed at an early stage disease. MSI tumors were characterized by loss of expression of MLH1 and an elevated DNA methylation signature. The MSI subtype was associated with the presence of hypermutation, with mutations of ARID1A (44.2%), the PI3K-PTEN-mTOR pathway (42%), KRAS (23.3%)and ALK (16.3%).

    The MSS/EMT subtype was observed at significantly younger age, with diffuse histology at stage III/IV and showed CDH1 loss of expression. The EMT subtype presented a lower number of mutation events when compared to the other MSS groups. The MSS/EMT had the worst prognosis, while the MSI subtype showed the best prognosis of the four. The authors observed that the MSS/EMT group presented a higher percentage of recurrence vs the MSI group (63% vs 23%). The MSS/EMT GC subtype was associated to a higher frequency of peritoneal metastases compared to all other subtypes, while a higher percentage of liver-limited metastasis in the MSI and MSS/TP53 subtypes was found.

    MSS/TP53 positive and MSS/TP53 negative showed an intermediate prognosis and also an intermediate chance of recurrence. EBV infection was more frequently associated to MSS/TP53 positive group. MSS/TP53 negative subtype exhibited the highest prevalence of TP53 mutations (60%) and a low frequency of other mutations,as well as recurrent focal amplification of ERBB2, EGFR, CCNE1, CCND1, MDM2,ROBO2, GATA6 whereas the MSS/TP53 positive subtype showed a relative higher(compared to MSS/TP53 negative) of mutations in APC, ARID1A, KRAS, PIK3CA and SMAD4.

    Comparison between the TCGA and ACRG classification

    Comparisons between TCGA and ACRG genomic subtypes showed similarities and differences (Figure 1). Both molecular classifications revealed MSI positive tumors and TCGA GS, EBV and CIN subtypes are likely to be approximated to ACRG MSS/EMT, MSS/TP53 positive and MSS/TP53 negative subtypes, respectively.Tumors classified as the GS subtype in the TCGA set were present across all ACRG subtypes in the ACRG data set, while tumors classified as the TCGA CIN subtype were present across all ACRG subtypes in the TCGA data set. A substantially lower percentage of Lauren's diffuse subtype cases were found in the TCGA cohort compared to ACRG database (24% vs 45% respectively) with the majority (57%) of Lauren's diffuse-sub-type cases present in the TCGA GS group but only 27% cases present in the ACRG MSS/EMT subtype. Additionally, CDH1 and RHOA mutations,which were mutated in TCGA GS, were infrequent in the ACRG MSS/EMT subtypes.These differences suggest that TCGA GS type is not equivalent to the ACRG MSS/EMT subtype.

    Collectively, these findings confirm that the TCGA and ACRG classification systems are related but distinct in terms of demographics, molecular mechanisms,driver genes and prognosis. Although these novel classifications have provided a deeper understanding of GC biology, some limitations can be observed. First, these analyses are based on complex molecular technologies and could not be replied in standard laboratories. Furthermore, a prospective validation on large scale including patients of different age and ethnicity is needed. Finally TCGA and ACRG classifications are the result of comprehensive molecular analysis on malignant GC epithelial cells that don't consider the impact of peritumoral stromal cells. Of note,novel stromal gene signatures have been analyzed in comparison to the dominant cancer phenotypes identified by TCGA and ACRG, revealing distinct stromal phenotypes[24,25].

    CURRENT STANDARD TREATMENTS IN METASTATIC GC

    Chemotherapy remains the backbone of therapy in patients with metastatic GC and good performance status. Available data from randomized clinical trials showed a statistically significant benefit of palliative chemotherapy, compared with best supportive care (BSC), in terms of symptom control, improvement of quality of life(QoL) and overall survival (OS).

    In the first line setting a variety of cytotoxic drugs, including platinum compounds,fluoropyrimidines, anthracyclines, taxanes, and irinotecan, have shown activity in GC. Currently, a combination including a platinum compound (cisplatin or oxaliplatin) plus a fluoropyrimidine (5-FU,capecitabine, or S-1) agent is one of the most widely used doublet on the basis of a balanced benefit-to risk ratio[26].

    Figure 1 The cancer genome atlas and the Asian cancer research group molecular classification of gastric cancer. EBV: Epstein-Barr; CIN: Chromosomal instability; MSI: Microsatellite instability; GS: Genomically stable tumours; MSS/EMT: Microsatellite unstable type, epithelial to mesenchymal-like type.

    Currently, trastuzumab is the only molecularly targeted drug accepted in first-line therapy, in combination with cisplatin and a fluoropyrimidine, for the treatment of patients with metastatic HER2-overexpressing GC or GEJC who have not received anti-cancer treatment for their metastatic disease. As a result, all cases of advanced GC should be characterized for HER2 status. HER2 is a member of the epidermal growth factor receptors (EGFRs) family and is involved in transmembrane signaling,and overexpression/activation leads to increased cell proliferation, growth and survival[27]. HER2 overexpression or/and amplification is found in approximately 20%of metastatic GC, although there are differences depending on tumor subtype, is more common in intestinal GC than diffuse GC, and more common in GEJC than distal GC[28].

    The phase III, open-label, randomised controlled ToGA trial (Trastuzumab for GC)compared in a population of 594 previously untreated patients standard chemotherapy (six courses of cisplatin plus either infusional fluorouracil or capecitabine) with and without trastuzumab until disease progression. All end points were improved with the addition of trastuzumab to chemotherapy, including objective response rate (ORR) (47.3% vs 34.5%), PFS (6.7 vs 5.5 mo; HR: 0.71; 95%IC:0.59-0.85; P < 0.0002), and at a median follow-up of 17 to 19 mo, median OS was significantly better with trastuzumab (13.8 vs 11.1 mo) (HR: 0.74; 95%CI: 0.60-0.91; P =0.0046). The inclusion criteria of the ToGA trial were a 3+ HER2 immunohistochemical (IHC) overexpression or the presence of HER2 gene amplification as assessed by fluorescent in situ hybridization (FISH), irrespective of IHC score[29].

    Despite the demonstrated efficacy of numerous chemotherapy options, only 40% of patients who progressed to first-line chemotherapy are susceptible to a second-line chemotherapy on progression[30]. In this setting, ramucirumab, a fully human monoclonal antibody VEGFR-2 antagonist, is the only molecular-targeted drug with a confirmed, although modest, survival benefit.

    The activity of ramucirumab, in second-line treatment of GC was investigated by the phase III REGARD trial (Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma), a randomized,double-blind, placebo-controlled study. In the REGARD trial 355 patients with previously treated advanced GC or GEJC adenocarcinomas were randomized to best supportive care plus either ramucirumab or placebo. Median OS was 5.2 mo in the ramucirumab arm and 3.8 mo in the placebo arm (HR: 0.78; 95%CI: 0.603-0.998; P =0.047)[31]. However, the RAINBOW trial (Ramucirumab plus paclitaxel vs placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma) was the landmark study that demonstrated the benefit of ramucirumab in second line setting in combination with chemotherapy, which compared weekly paclitaxel (80 mg/m2on days 1, 8, and 15 of each 28-day cycle) plus ramucirumab (8 mg/kg IV every two wk) or placebo in 665 patients. Median OS and PFS were significantly longer in patients treated with ramicurumab than in the placebo-plus-paclitaxel group (median OS: 9.6 vs 7.4 mo, HR: 0.81, 95%CI: 0.678-0.962,P = 0.017 and median PFS 4.4 vs 2.9 mo, HR: 0.635, 95%CI: 0.539-0.752, P ≤ 0.001,respectively)[32].

    Largely based on this trial results, ramucirumab plus paclitaxel is currently the preferred choice for second-line therapy. More recently, the phase III TAGS study(Trifluridine/tipiracil vs placebo in patients with heavily pretreated metastatic GC)proved that trifluridine/tipiracil is an effective treatment option for patients with heavily pretreated metastatic GC. The study demonstrated a 31% reduction in risk of death and a 2.1-month improvement in median OS in treated patients[33].

    HER2: PRIMARY AND ACQUIRED RESISTANCE

    The anti-HER2 monoclonal antibody trastuzumab plus standard chemotherapy have significantly improved response rate and survival outcomes in primary GC and GEJC displaying HER2 overexpression/amplification. Unfortunately, about 50% of patients did not respond to the combination treatment suggesting the existence of a primary resistance[29]. At same time, acquired resistance usually limits the duration of response to this treatment.

    Genomic alterations of the RTK pathway such as EGFR, FGFR2, MET, and KRAS amplification may be responsible for primary resistance to HER2-targeting drugs[14].Recently, amplifications of cell-cycle-related genes such as CCNE1 and CDK6, PI3K mutations, and amplification of MET have shown to confer resistance to anti-HER2 agents in vitro HER2-amplified cell-line models[34]. Although uncommon, other rare alterations in RTK pathways such as ALK, ROS1, NTRK1/2/3 and RET fusion could be correlated with primary resistance to trastuzumab[35-37]. To confirm these data, a recent study investigated a panel of genomic alterations including mutations in the EGFR /MET / KRAS / PI3K / PTEN genes and amplifications in EGFR / MET / KRAS in 37 patients treated with trastuzumab (17 responders and 20 patients with primary resistance). Interestingly, panel alterations were significantly more frequent in resistant (11 of 20, 55%) as compared with sensitive patients and in HER2 IHC 2+ than 3+ tumors. Patients with no alteration had a significantly longer median PFS and OS[38].

    Mechanisms of acquired resistance to anti-HER2 treatment in GC are largely unknown. Pietrantonio et al[39]have analyzed 22 matched tumor samples taken at baseline and post-progression in patients receiving chemotherapy and trastuzumab for advanced HER2 IHC 3+ or 2+ GC. Loss of HER2 was identified as a mechanism of resistance in 32% of samples and the probability of loss of HER2 positivity was significantly higher in patients with baseline IHC score 2+ vs 3+. Similarly, loss of HER2 and frequent secondary alterations in the RTK/RAS/PI3K pathway in HER2 positive adenocarcinoma have been observed in patients treated with trastuzumab[40].

    In a recent study evaluating capecitabine and oxaliplatin as first line neoadjuvant therapy in patients with previously untreated, HER2-positive GC, the analysis of circulating free DNA (cfDNA) at disease progression demonstrated the emergences of genomic aberrations such as MYC, EGFR, FGFR2 and MET amplifications[41].However, none of these biomarkers is evaluated in the current clinical practice.

    Other anti-HER2 strategies have failed to demonstrate a clinical benefit in second line HER2 positive GC. In the GATSBY trial (Trastuzumab emtansine vs taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastrooesophageal junction adenocarcinoma) the antibody-drug conjugate consisting of the monoclonal antibody Trastuzumab linked to microtubule inhibitor emtansine (TDM1) compared to taxans, failed to prolong survival in patients with previously treated HER2-positive advanced GC[42]. In the phase III randomized TyTAN trial(Lapatinib plus paclitaxel vs paclitaxel alone in the second-line treatment of HER2-amplified advanced GC in Asian populations) comparing the efficacy and safety of the tyrosine kinase inhibitor of EGFR and HER2 Lapatinib plus paclitaxel with paclitaxel alone, the combination treatment demonstrated activity in the second-line but did not significantly improve OS in the intent-to-treat population (ITT)[43].Moreover, in a recent trial comparing weekly paclitaxel alone with weekly paclitaxel plus Trastuzumab in patients with HER2-positive advanced GC/GEJC progressing during Trastuzumab-containing therapy, Trastuzumab beyond progression strategy did not improve PFS[44].

    Results from ongoing phase III (NCT01774786) and phase II (NCT01522768) clinical trials of Pertuzumab and Afatinib respectively, will hopefully contribute to the unmet need in this setting of patients whose therapeutic options still remain limited (Table 1).

    RTK/RAS - TARGET THERAPIES

    CIN tumors are frequently characterized by the presence of activation of the RTK/RAS pathway and EGFR, HER2, HER3, JAK2, MET, FGFR2, PIK3CA and KRAS/NRAS amplification[14]. Other works have reported that at least one third of GC patients present alterations of the RTK/RAS pathway and may be potentially treatable by directed therapies[45]. Unfortunately, most of phase II and III trials evaluating RTK/RAS target therapies failed to demonstrate activity in metastatic GC.

    The EGFR gene is amplified in the 5% and EGFR is overexpressed in more than 30% of GC[14,46]. Both anti-EGFR drug cetuximab and panitumumab have been tested in two phase III trial. In the EXPAND trial (Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced GC), the addition of the chimeric monoclonal antibody cetuximab to capecitabine-cisplatin provided no additional benefit in terms of PFS to chemotherapy alone in the first-line treatment of advanced GC (HR: 1.09; 95%CI: 0.92-1.29; P = 0.32)[47]. The REAL 3 trial (Epirubicin,oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer), with 553 patients randomized to receive epirubicin, oxaliplatin, and capecitabine (EOC) plus the human monoclonal antibody panitumumab or EOC alone, failed to show a benefit in OS of the combination therapy compared with the only chemotherapy (HR: 1.37; 95%CI:1.07-1.76; P = 0.013)[48]. However, none of these studies have selected patients on the basis of EGFR overexpression/amplification. In metastatic colorectal cancer, RAS mutations are a negative predictive biomarkers of response to anti-EGFR therapy but can be detected only in about 3% of GC and GEJC.

    Several works have reported that EGFR expression, EGFR gene copy number, or expression of other EGFR ligands such as epiregulin and amphiregulin, might be potential markers for efficacy of anti-EGFR target therapies[49-51]. However, in the EXPAND trial, no substantial differences between the treatment groups for PFS or OS according to EGFR immunohistochemistry score was noted[47]. Results from a phase III trial comparing the efficacy of nimotuzumab, a recombinant humanized anti-EGFR antibody, and irinotecan on irinotecan alone in patients with EGFR overexpressed advanced GC/GEJC are expected (ENRICH study, NCT01813253, Table 1).

    The tyrosine kinase receptor c-MET and its own ligand, hepatocyte growth factor(HGF), have been investigated as potential target in advanced GC. In GC, alteration of the MET/HGF pathway is related to a more aggressive disease and poor prognosis,with MET activation stimulating tumor invasiveness[52,53]. Onartuzumab, a monovalent monoclonal antibody binding with the extracellular of MET, has been tested in a phase III trial of 562 patients randomized to receive onartuzumab plus FOLFOX6 vs placebo plus mFOLFOX6 in patients with metastatic HER2-negative and METpositive GEC. However, the addition of onartuzumab to mFOLFOX6 did not attain significant differences in OS or PFS compared with placebo plus mFOLFOX6 in ITT(OS HR: 0.82; 95%CI: 0.59-1.15; P = 0.24; PFS HR: 0.90; 95%CI: 0.71-1.16; P = 0.43) or MET 2+/3+ populations (OS HR: 0.64; 95%CI: 0.40-1.03; P = 0.06; PFS HR: 0.79;95%CI: 0.54-1.15; P = 0.22)[54]. The RILOMET phase III trial (Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer), evaluating the fully human monoclonal antibody anti-MET Rilotumumab plus epirubicin, cisplatin, and capecitabine or placebo plus epirubicin, cisplatin, and capecitabine as first line in advanced GC, was ceased subsequently the finding by an independent data monitoring committee of a higher number of deaths in the rilotumumab group compared with the placebo group[55].

    Table 1 Ongoing phase II/III target trials in advanced gastric cancer

    Approximately 5%-10% of GCs present an fibroblast growth factor receptor-2 (FGFR2)gene amplification, which appears to confer poor prognosis[56-58]. The selective FGFR-1,2, 3 tyrosine kinase inhibitor AZD4547 showed potent activity in preclinical models[59].The randomized phase II SHINE study (Efficacy and Safety of AZD4547 vs Paclitaxel in Patients With Advanced Gastric or Gastro-oesophageal Cancer) comparing AZD4547 vs paclitaxel as second-line treatment in patients with advanced GC displaying FGFR2 polysomy or gene amplification did not demonstrated a PFS improvement in the experimental arm (1.8mo with AZD4547 vs 3.5mo with paclitaxel;HR: 1.57; 80%CI: 1.12-2.21; P = 0.9581)[60].

    IMMUNOTHERAPY

    GCs/GEJCs are associated with immune system evasion and overexpression of immune checkpoint proteins including the programmed death ligand 1 (PD-L1) and programmed death ligand 2 (PD-L2) expressed on the surface of tumor and immune cells. An high expression of PD-L1 has been reported in both Western and Asian GC/GEJC cohorts and has been associated with an elevated tumor mutational burden(TMB) and specific subtypes of adenocarcinomas[61,62]. The binding of PD1, a protein of CD28 family expressed on T cells functioning as a negative costimulatory receptor,and its ligands-PD-L1 and PD-L2, can inhibit cytotoxic T-cell responses, allowing tumor cells to evade immune surveillance. Checkpoint inhibitors such as antibodies anti PD1 (pembrolizumab, nivolumab) and PD-L1 (atezolizumab, avelumab,durvalumab) and inhibitors of cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4,like ipilimumab) have demonstrated to antagonize this immune tolerance, which results in an enhanced antitumor effect. In the last years, checkpoint inhibitors have shown activity in several solid tumors and have received approval for a number of clinical indications including advanced melanoma, renal cell carcinoma and nonsmall lung cancer (NSCLC)[63].

    Since their introduction in the treatment scenario, lots of efforts have been undertaken to establish predictive biomarkers of response to these novel agents.Combined data from disease-specific trials with the humanized IgG4 monoclonal antibody pembrolizumab, demonstrated that tumors with a large number of somatic mutations due to high microsatellite instability (MSI-H) or mismatch repair deficiency(dMMR) are susceptible and can benefit to immune checkpoint blockade. On these findings, in 2017 FDA decided to accelerate the approval to Pembrolizumab for patients with unresectable or metastatic solid tumours with positive dMMR or MSI-H biomarkers[64]. Other studies have shown that PD-L1 expression on the membranes of tumor cells or tumor-infiltrating immune lymphocytes (TILs) was associated with a better OS in certain types of tumours treated with checkpoint inhibitors. However,there is currently no consensus on the role of PD-L1 expression as prognostic and predictive biomarker in advanced GC[65].

    In GC, checkpoint inhibitors have been firstly assessed in the salvage setting showing a rather wide range of response rate (11.6%-22%)[66,67]. In the phase III Asian ATTRACTION-2 trial (Nivolumab in patients with advanced gastric or gastrooesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens) 493 patients with refractory GC to two or previous chemotherapy regimens were randomized to receive nivolumab (n = 330) or placebo(n = 163) resulting in a median OS of 5.26 mo (95%CI: 4.60-6.37) in the nivolumab group and 4.14 mo (3.42-4.86) in the placebo group (HR: 0.63; 95%CI: 0.51-0.78; P <0.0001). The OS rates of nivolumab and placebo were 27.3% and 11.6% at 12 mo, and 10.6% and 3.2% at 24 mo, respectively. Based on these results, nivolumab was granted accelerated approval in Japan, South Korea and Taiwan for the treatment of advanced GC progressed to standard chemotherapy[68].

    Moreover, Pembrolizumab has recently received accelerated approval by FDA considering the promising results of the KEYNOTE-059 trial (Safety and Efficacy of Pembrolizumab Monotherapy in Patients with Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer). In this phase II, single arm study, 259 patients with advanced GC or GEJC whose disease progressed to two or more lines of therapy, received pembrolizumab every 3 wk achieving an objective response rate(ORR) of 11,6 % (95%CI: 8.0%-16.1%; n = 30/259) with complete response in 2.3%(95%CI: 0.9%-5%; n = 6/259) and manageable safety. Interestingly, patients with PDL1 positive tumors (PD-L1 combined positive score ≥ 1) had an ORR of 22.7% (95%CI:13.8-33.8) and patients PD-L1-negative had an ORR of only 8.6% (95%CI: 2.9-19.0).Excluding MSI-H tumors (ORR of 57%, 4 of 7 patients) from that group, the percentage of response to pembrolizumab decreased to 13.3% in PD-L1 positive microsatellite stable (MSS) (or MSI status not available) patients, and 9% (15 of 167) of MSS patients independently of PD-L1 status responded, confirming the importance of the microsatellite status as marker of response to checkpoint inhibitors[66].

    Despite the initial enthusiasm, some randomized phase III trial reported negative outcomes with checkpoint inhibitors when compared to chemotherapy. The KEYNOTE-061 phase III trial (Pembrolizumab vs paclitaxel for previously treated,advanced gastric or gastro-oesophageal junction cancer) comparing pembrolizumab vs chemotherapy with weekly paclitaxel as second line treatment in patients with GC or GEJC with PD-L1 positivity in at least 1 % of tumor cells, failed to improve OS and PFS[69]. Similarly, the randomized, phase III Javelin Gastric 300 trial comparing the anti-PD-L1 IgG1 monoclonal antibody Avelumab vs chemotherapy as third line therapy in 379 patients with advanced GC/GEJC, did not meet its primary endpoint of improving OS or the secondary end points of PFS[70].

    In the TCGA study an high level of intra- or peritumoral immune cell infiltration and frequent amplification of the CD274 gene (which encodes PD-L1) and the PDCD1LG2 gene (which encodes PD-L2) in the EBV-positive subgroup GC was found[14]. Furthermore, subsequent studies confirmed remarkable PD-L1 expression both in cancer and immune cells in EBV positive GCs[71]. Consistent with these findings, a prospective phase II Korean clinical trial of pembrolizumab with whole exome and RNA sequencing in pre and post biopsy specimens was performed to better define those patient who may benefit from pembrolizumab. Among 61 patients with advanced GC that received pembrolizumab as a second or greater line of treatment, those with MSI-H and EBV positive tumours, which are mutually exclusive, showed dramatic responses to pembrolizumab with ORR of 85.7% (6/7) in the MSI-H group and of 100% (6/6) EBV positive GCs. In addition for the 55 patients for whom PD-L1 combined positive score positivity (cut off value ≥ 1) was available,ORR was significantly higher for PD-L1 positive (n = 28) tumors when compared to PD-L1 negative (n = 27) GCs (50.0% vs 0.0%, P < 0.001)[72]. Although this study have provided the first clinical evidence of high activity of pembrolizumab EBV positive GCs, the percentage of EBV positive or MSI-H GCs was higher in this patient cohort compared to Western cohorts. This can be explained at least in part with the different regional risk of acquiring EBV associated GCs that ranges from 1.3%-30.9% (average of 10% worldwide) with the highest risk in Far East Asia, which also presents the highest incidence of GCs[73].

    In order to optimize treatment strategies with checkpoint inhibitors, a number of ongoing trials are evaluating these agents in the first line setting (NCT02872116,NCT02746796, NCT02625610, NCT02494583, Table 1). Novel predictive biomarker are needed to select patient subgroups most likely to benefit from checkpoint inhibitors.Recently, Sundar et al. reported that epigenomic promoter alterations occur in a substantial proportion of metastatic GCs and cause reduced expression immunogenic peptides, which allow immune evasion and remarkable resistance to anti-PD1 immune checkpoint inhibition[74].

    CLAUDIN 18.2

    Claudins are main components of tight junctions in epithelial cellular sheets. Distinct claudins isoforms have been identified in different organs and their altered function has been discovered to be associated to the cancerogenesis of respective tissues[75,76].Claudin 1-5, 7-12,16 and 18 proteins are expressed in healthy gastric tissue[77]. In particular the isoform 2 of the tight junction molecule Claudine-18 (CLDN18.2) is strictly confined to differentiated gastric epithelial cells where controls the paracellular permeability to Na+and H+. In a significant percentage of primary GCs and metastases, the cell polarity perturbations lead to exposure of CLDN18.2 on the surface of GC cells so that it is available for monoclonal antibody binding[78].CLDN18.2 is not exclusive of GC and is broadly expressed in various cancer types including biliary duct, pancreatic, ovarian cancer and NSCLC. A recent work have analyzed 286 GC/GEJC tissue samples from North America, Asia and Europe,demonstrating that 30% of samples (n = 86/286) presented high expression CLDN18.2(moderate-to-strong CLDN18.2 membrane staining in ≥ 75% of tumor cells) with limited overlap with HER2[79]. These biological findings suggested that CLDN18.2 could be targetable and led to the further development of monoclonal antibodies against this protein. Zolbetuximab (IMAB362) is an anti-CLDN18.2 antibody that binds GC cell lines with high relative affinity and selectivity, then mediates a lysis of CLDN18.2-positive cells through antibody-dependent cellular cytotoxicity (ADCC)and complement-dependent cytotoxicity (CDC). In the phase II FAST trial a total of 161 patients were randomized to receive zolbetuximab plus epirubicine and oxaliplatin (EOX) or EOX alone. Median PFS was significantly higher with zolbetuximab + EOX (7.5 mo) vs EOX alone (5.3 mo; P < 0.0005; HR: 0.44, 95%CI: 0.29-0.67) and median OS (13 vs 8.4 mo; P = 0.0008; HR: 0.56, 95%CI: 0.40-0.79) and ORR(39 vs 25%; P = 0.022) were also demonstrated to be longer with zolbetuximab + EOX vs EOX alone with an increased efficacy in patients with high CLDN18.2 expression[80].Consistent with these results, several trials are investigating zolbetuximab in different setting (NCT03504397, NCT03504397, NCT03653507, Table 1).

    ANGIOGENIC AND STROMAL INHIBITORS

    Based on the positive results of the REGARD and RAINBOW trial, other agents were assessed for angiogenic inhibition in GC. The VEGFR-2 tyrosine kinase inhibitor apatinib was tested in a phase II trial of patients with advanced GC refractory to two or more lines of prior chemotherapy, showing compared to placebo, prolonged OS(6.5 mo; 95%CI: 4.8 -7.6 vs 4.7 mo; 95%CI: 3.6-5.4; P = 0.0149; HR: 0.709; 95%CI: 0.537-0.937; P = 0.0156) and PFS (2.6 mo; 95%CI: 2.0-2.9 vs 1.8 mo; 95%CI: 1.4-1.9; P < 0.001;HR: 0.444; 95%CI: 0.331-0.595; P < 0.001)[81]. The ongoing ANGEL phase III trial(Efficacy and Safety Trial of Apatinib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Patients With Gastric Cancer) is evaluating the clinical benefit and safety of apatinib plus Best Supportive Care (BSC) in comparison to placebo plus BSC in patients who failed to at least two prior lines of standard chemotherapies (NCT03042611, Table 1). Other phase III trials are assessing the efficacy of apatinib as maintenance treatment after first line induction therapy(NCT03598348, NCT02510469, NCT02509806). Regorafenib is an oral multi-kinase inhibitor which targets angiogenic (VEGFR-1 and -2, tie-2), stromal (PDGF-β) and oncogenic RTK, largely used in metastatic colorectal cancer and GIST. In the INTEGRATE phase II study (Regorafenib for the treatment of advanced GC) patients with previously treated GC had statistically significantly improved PFS when treated with regorafenib compared to placebo [2.6 vs 0.9 mo (HR: 0.40; 95%CI: 0.28-0.59;stratified log-rank: P < 0.001)][82]. Consistent with these results, regorafenib is currently evaluated in the INTEGRATE II phase III trial (NCT02773524, Table 1). Bevacizumab is a recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting VEGF-A. The AVAGAST and AVATAR trials, comparing the VEGFantibody bevacizumab plus cisplatin/capecitabine to chemotherapy alone in different populations, failed to show significant benefit in OS[83,84]. Subgroup analysis of the AVAGAST trial showed that non-Asian patients were more likely to benefit from an anti-angiogenic therapy than Asian patients, although in the overall study population,this effect was not observed. Despite the encouraging results in the second line setting, in the recent phase III trial RAINFALL (Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma) that randomized patients to receive ramucirumab plus fluoropyrimidine and cisplatin or placebo plus fluoropyrimidine and cisplatin as firstline treatment, the addiction of ramucirumab to chemotherapy did not demonstrated a statistical significant advantage in PFS (HR: 0.961, 95%CI: 0.768-1.203, P = 0.74) and OS [HR: 0.962, 95%CI: 0.801-1.156, P = 0.6757; median OS 11.2 mo (9.9-11.9) in the ramucirumab group vs 10.7 mo (9.5-11.9) in the placebo group][85]. Other studies have investigated innovative approach to target the tumor microenvironment. A phase I/Ib study found that the addition of andecaliximab, a monoclonal antibody that inhibits matrix metalloproteinase 9, to FOLFOX showed activity in GC and GEJC.Unfortunately the phase III GAMMA-1 trial (A phase III, randomized, double-blind,placebo-controlled study to evaluate the efficacy and safety of andecaliximab combined with mFOLFOX6 as first-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma) comparing FOLFOX6 plus andecaliximab or mFOLFOX6 plus placebo showed a median OS of 12.5 vs 11.8 mo in the andecaliximab vs placebo treatment groups, respectively (HR: 0.93, two-sided: P =0.56) and a median PFS of 7.5 mo in the andecaliximab group vs 7.1 mo in the placebo group (HR: 0.94, two-sided: P = 0.10)[86].

    CONCLUSION

    Recent high-throughput molecular profiling studies have provided a deeper understanding of the multiple genomic and epigenetic landscape of this complex and heterogeneous disease. New gene mutations, chromosomal aberrations,transcriptional and epigenetic alterations have been described with potentially implications for the development of personalized treatment options. However, at present, few target therapies are still available for metastatic GC.

    Researches are focusing on the comprehension of primary and acquired mechanisms of resistance to anti-HER2 drugs. Moreover the targeting of other RTKs such as EGFR, MET or FGFR by TKIs or monoclonal antibodies failed to demonstrate a clinical benefit in GC. However, an appropriate molecular selection have not been conducted in many target driven clinical trials and retrospective analyses of these studies have provided a potential benefit from RTK-inhibitors in molecularly selected subgroups.

    It has to be noted that an excessive GC tumor heterogeneity and evolution complicates the efficacy of target strategies. Recent studies showed a significant discrepancy in genomic alterations within the primary tumor and between the primary tumor and disseminated disease and the potential use of plasma-based circulating-tumor DNA (cfDNA) to enhance selection of therapy in GC[41,87].

    Based on the promising results of clinical trials of patients with pretreated advanced GC, pembrolizumab and nivolumab were granted accelerated approval in in the United States and in some Asian countries respectively. In contrast, none of the current checkpoint inhibitors have been approved by the European Medicines Agency(EMA). As demonstrated in other solid tumors, GC with MSI-H or dMMR is more likely to respond to checkpoint inhibitors. EBV positive GCs seem to benefit significantly from these drugs, while the role of PD-L1 expression as prognostic and predictive biomarker of response to checkpoint inhibitors has not confirmed in all the studies. In addition, epigenomic promoter alterations have been recently described as a novel potential mechanism of resistance to checkpoint inhibitors in a substantial proportion of GC. The anti-CLDN18.2 antibody zolbetuximab has shown promising results and it is currently investigated in different ongoing trials. As regard angiogenesis, in addition to ramucirumab, other antiangiogenic agents including apatinib and regorafenib are currently under investigation.

    In conclusion, remarkable advances in the molecular characterization of GC have expanded our knowledge and paved the way to novel treatment options that will hopefully improve the survival outcomes of patients with metastatic GC.

    久久香蕉激情| 在线av久久热| 色播在线永久视频| 亚洲一区二区三区色噜噜 | 国产极品粉嫩免费观看在线| 黄色毛片三级朝国网站| 国产99白浆流出| 男女做爰动态图高潮gif福利片 | 后天国语完整版免费观看| 熟女少妇亚洲综合色aaa.| 91九色精品人成在线观看| 一进一出抽搐gif免费好疼 | 欧美性长视频在线观看| 亚洲欧美日韩无卡精品| 亚洲精品中文字幕一二三四区| 免费在线观看黄色视频的| 久久人妻av系列| 欧美精品亚洲一区二区| 午夜福利一区二区在线看| 亚洲七黄色美女视频| 国产麻豆69| 人妻丰满熟妇av一区二区三区| 亚洲精品成人av观看孕妇| 男人舔女人下体高潮全视频| 最近最新免费中文字幕在线| 国产精品 欧美亚洲| 色婷婷久久久亚洲欧美| 国产精品香港三级国产av潘金莲| 久久久久久久久久久久大奶| 高清在线国产一区| 成人特级黄色片久久久久久久| av欧美777| 俄罗斯特黄特色一大片| 少妇的丰满在线观看| 好看av亚洲va欧美ⅴa在| 伊人久久大香线蕉亚洲五| 亚洲久久久国产精品| www.www免费av| 夫妻午夜视频| 成人特级黄色片久久久久久久| 免费av毛片视频| 国产精品久久久久久人妻精品电影| 在线av久久热| 水蜜桃什么品种好| 久久中文看片网| 国产黄色免费在线视频| 黄色怎么调成土黄色| 丰满饥渴人妻一区二区三| 国产精品久久久人人做人人爽| 久久精品国产亚洲av高清一级| 久久久久久亚洲精品国产蜜桃av| 日韩精品中文字幕看吧| 在线观看免费视频网站a站| 久久久久久久久久久久大奶| 黑人欧美特级aaaaaa片| 三上悠亚av全集在线观看| 国产欧美日韩精品亚洲av| 青草久久国产| 91精品国产国语对白视频| 少妇粗大呻吟视频| 日韩视频一区二区在线观看| 女人被狂操c到高潮| 精品久久久精品久久久| 精品国产一区二区三区四区第35| 久久精品成人免费网站| 久久青草综合色| 国产成人欧美| 亚洲精品美女久久久久99蜜臀| 男人的好看免费观看在线视频 | 天天添夜夜摸| 狂野欧美激情性xxxx| 欧美 亚洲 国产 日韩一| 亚洲自拍偷在线| 国内毛片毛片毛片毛片毛片| 亚洲欧美精品综合久久99| 欧美国产精品va在线观看不卡| 美女大奶头视频| 免费女性裸体啪啪无遮挡网站| 欧美中文日本在线观看视频| 在线十欧美十亚洲十日本专区| 国产在线观看jvid| 亚洲一区二区三区欧美精品| 我的亚洲天堂| 日韩欧美国产一区二区入口| 男女之事视频高清在线观看| 欧美大码av| 精品国产亚洲在线| 色综合站精品国产| 亚洲欧美精品综合久久99| 曰老女人黄片| 欧美黄色片欧美黄色片| av福利片在线| 好看av亚洲va欧美ⅴa在| 国产精品久久久av美女十八| cao死你这个sao货| 黄片播放在线免费| 黑人巨大精品欧美一区二区蜜桃| 国产成人精品无人区| 多毛熟女@视频| 欧美成人午夜精品| 女生性感内裤真人,穿戴方法视频| 免费在线观看黄色视频的| 亚洲av成人一区二区三| 日本欧美视频一区| 亚洲人成电影观看| 丝袜美足系列| 国产又色又爽无遮挡免费看| 91国产中文字幕| 精品国内亚洲2022精品成人| 日本五十路高清| 午夜亚洲福利在线播放| 中文字幕最新亚洲高清| 亚洲专区中文字幕在线| 亚洲av第一区精品v没综合| 成人三级做爰电影| 色哟哟哟哟哟哟| av有码第一页| 熟女少妇亚洲综合色aaa.| 女同久久另类99精品国产91| 亚洲熟妇熟女久久| 欧美中文日本在线观看视频| 日韩中文字幕欧美一区二区| 国产免费现黄频在线看| 一级片'在线观看视频| 国产精品98久久久久久宅男小说| 亚洲精品美女久久av网站| 视频区图区小说| 亚洲自偷自拍图片 自拍| 国产又爽黄色视频| 真人一进一出gif抽搐免费| 免费一级毛片在线播放高清视频 | 91av网站免费观看| 亚洲情色 制服丝袜| 少妇粗大呻吟视频| 99国产精品一区二区蜜桃av| 精品国内亚洲2022精品成人| 亚洲国产精品sss在线观看 | av免费在线观看网站| 免费在线观看完整版高清| 99香蕉大伊视频| 韩国av一区二区三区四区| 亚洲国产看品久久| 99riav亚洲国产免费| 夫妻午夜视频| 高清欧美精品videossex| 天天躁夜夜躁狠狠躁躁| 女生性感内裤真人,穿戴方法视频| 青草久久国产| xxxhd国产人妻xxx| 亚洲人成网站在线播放欧美日韩| 女人高潮潮喷娇喘18禁视频| 国产成年人精品一区二区 | 欧美精品亚洲一区二区| 丁香欧美五月| 国产精品爽爽va在线观看网站 | 欧美不卡视频在线免费观看 | 天堂中文最新版在线下载| 日本wwww免费看| 人妻丰满熟妇av一区二区三区| 成人特级黄色片久久久久久久| 日韩欧美一区二区三区在线观看| av网站免费在线观看视频| 久久久久国产一级毛片高清牌| 亚洲av成人一区二区三| 日本五十路高清| 国内毛片毛片毛片毛片毛片| 精品一区二区三区四区五区乱码| 又黄又粗又硬又大视频| 国产精品二区激情视频| 久久久久国产一级毛片高清牌| 麻豆成人av在线观看| 日韩三级视频一区二区三区| 国产成人啪精品午夜网站| 热re99久久精品国产66热6| 一个人免费在线观看的高清视频| 国产人伦9x9x在线观看| 亚洲自拍偷在线| 18禁裸乳无遮挡免费网站照片 | 精品国产一区二区久久| 亚洲色图av天堂| 亚洲精品美女久久久久99蜜臀| 最新在线观看一区二区三区| 老司机靠b影院| 欧美日韩乱码在线| 一级毛片女人18水好多| 久久亚洲精品不卡| 亚洲av熟女| 正在播放国产对白刺激| 亚洲国产精品sss在线观看 | 精品国产超薄肉色丝袜足j| 一个人免费在线观看的高清视频| 9色porny在线观看| 国产又爽黄色视频| 国产熟女午夜一区二区三区| 成年版毛片免费区| 亚洲人成77777在线视频| 午夜久久久在线观看| 欧美亚洲日本最大视频资源| 久久久久久久久久久久大奶| 看片在线看免费视频| 99re在线观看精品视频| 99久久国产精品久久久| 亚洲 欧美 日韩 在线 免费| 免费搜索国产男女视频| 中文字幕av电影在线播放| 在线观看一区二区三区| 极品人妻少妇av视频| a级毛片黄视频| 国产一区二区激情短视频| 校园春色视频在线观看| 国产精品影院久久| 亚洲色图 男人天堂 中文字幕| 香蕉久久夜色| 国产三级黄色录像| 国产激情久久老熟女| 老熟妇仑乱视频hdxx| 啪啪无遮挡十八禁网站| 欧美乱色亚洲激情| 女性生殖器流出的白浆| 国产在线精品亚洲第一网站| 婷婷六月久久综合丁香| 在线av久久热| 日韩精品青青久久久久久| 久久天躁狠狠躁夜夜2o2o| 久久久久久久久中文| 一进一出好大好爽视频| 精品午夜福利视频在线观看一区| 精品人妻1区二区| 大香蕉久久成人网| 水蜜桃什么品种好| а√天堂www在线а√下载| 50天的宝宝边吃奶边哭怎么回事| 丰满的人妻完整版| 久久久久国产一级毛片高清牌| 女人被躁到高潮嗷嗷叫费观| 丝袜人妻中文字幕| 色老头精品视频在线观看| 黄色视频不卡| 精品第一国产精品| 亚洲国产精品sss在线观看 | 国产精品综合久久久久久久免费 | 一区在线观看完整版| 久久精品亚洲熟妇少妇任你| 长腿黑丝高跟| 久久热在线av| 一级a爱片免费观看的视频| 别揉我奶头~嗯~啊~动态视频| 欧美日韩精品网址| 日本免费a在线| 欧美最黄视频在线播放免费 | 性欧美人与动物交配| 热re99久久精品国产66热6| 久久99一区二区三区| 中文字幕高清在线视频| 黄色视频不卡| 成年女人毛片免费观看观看9| 亚洲一区中文字幕在线| 国产伦人伦偷精品视频| 最新美女视频免费是黄的| 热re99久久精品国产66热6| 国产成人精品久久二区二区91| 在线观看免费高清a一片| 免费av毛片视频| 狂野欧美激情性xxxx| 精品电影一区二区在线| tocl精华| 中文亚洲av片在线观看爽| 久久人妻熟女aⅴ| 国产激情欧美一区二区| 亚洲久久久国产精品| 午夜成年电影在线免费观看| 亚洲成人免费av在线播放| 一区在线观看完整版| 亚洲欧美精品综合一区二区三区| 国产成人精品久久二区二区91| 精品国产国语对白av| 国产成年人精品一区二区 | 天堂动漫精品| 国产精品一区二区在线不卡| 黄色女人牲交| 少妇的丰满在线观看| 久久人人97超碰香蕉20202| 色精品久久人妻99蜜桃| 亚洲一区中文字幕在线| 在线看a的网站| 精品卡一卡二卡四卡免费| 88av欧美| 欧美久久黑人一区二区| 亚洲第一青青草原| 制服人妻中文乱码| 18禁国产床啪视频网站| 在线播放国产精品三级| 国产主播在线观看一区二区| 中出人妻视频一区二区| 丁香欧美五月| 中出人妻视频一区二区| 搡老岳熟女国产| bbb黄色大片| 999久久久精品免费观看国产| a级毛片在线看网站| 又黄又粗又硬又大视频| 午夜亚洲福利在线播放| 丝袜美足系列| 国产一区二区三区综合在线观看| 高潮久久久久久久久久久不卡| 久久天堂一区二区三区四区| 国内久久婷婷六月综合欲色啪| 亚洲欧美日韩无卡精品| www国产在线视频色| 午夜免费成人在线视频| aaaaa片日本免费| 12—13女人毛片做爰片一| 久久久久九九精品影院| 亚洲av五月六月丁香网| 人成视频在线观看免费观看| 91在线观看av| 丝袜美腿诱惑在线| 韩国av一区二区三区四区| 一进一出好大好爽视频| 日本wwww免费看| 手机成人av网站| 国产免费av片在线观看野外av| 午夜老司机福利片| 麻豆成人av在线观看| 国产精品九九99| 国产单亲对白刺激| 亚洲欧美日韩另类电影网站| av有码第一页| 欧美另类亚洲清纯唯美| 色哟哟哟哟哟哟| 亚洲国产精品一区二区三区在线| 精品第一国产精品| 国产三级在线视频| 日韩高清综合在线| 精品日产1卡2卡| 精品国产亚洲在线| 91精品三级在线观看| 欧美丝袜亚洲另类 | 国产一区二区三区在线臀色熟女 | 美女午夜性视频免费| www.www免费av| 亚洲国产欧美网| 97人妻天天添夜夜摸| 国产在线精品亚洲第一网站| 婷婷精品国产亚洲av在线| 一区二区三区精品91| 97人妻天天添夜夜摸| 国内毛片毛片毛片毛片毛片| 久久国产精品人妻蜜桃| 在线观看一区二区三区| 老司机午夜十八禁免费视频| 悠悠久久av| 一级,二级,三级黄色视频| 人妻丰满熟妇av一区二区三区| 搡老岳熟女国产| 色婷婷av一区二区三区视频| 999久久久国产精品视频| 久久午夜亚洲精品久久| 欧美精品啪啪一区二区三区| 淫秽高清视频在线观看| 国产精品一区二区在线不卡| 99国产极品粉嫩在线观看| av福利片在线| 日韩中文字幕欧美一区二区| 男女下面插进去视频免费观看| xxxhd国产人妻xxx| 美女午夜性视频免费| 黄色片一级片一级黄色片| 女同久久另类99精品国产91| 国产精品二区激情视频| 欧美一级毛片孕妇| 妹子高潮喷水视频| 天堂中文最新版在线下载| 亚洲色图综合在线观看| av天堂在线播放| 99国产精品一区二区蜜桃av| 黄色丝袜av网址大全| 丝袜在线中文字幕| 嫩草影院精品99| 亚洲精品国产一区二区精华液| 国产精品98久久久久久宅男小说| a级片在线免费高清观看视频| 波多野结衣一区麻豆| 热re99久久国产66热| 亚洲精品一区av在线观看| 69av精品久久久久久| 成熟少妇高潮喷水视频| 黄网站色视频无遮挡免费观看| 一二三四社区在线视频社区8| 很黄的视频免费| 757午夜福利合集在线观看| 精品乱码久久久久久99久播| 国产成人av教育| 日韩国内少妇激情av| 精品一品国产午夜福利视频| 久久久久久久久久久久大奶| 亚洲情色 制服丝袜| 99国产极品粉嫩在线观看| 男人操女人黄网站| 757午夜福利合集在线观看| 人人妻人人爽人人添夜夜欢视频| 日本vs欧美在线观看视频| 中文亚洲av片在线观看爽| 日日干狠狠操夜夜爽| 亚洲色图综合在线观看| av视频免费观看在线观看| 性少妇av在线| 亚洲 欧美 日韩 在线 免费| 黄频高清免费视频| 一级毛片女人18水好多| 黄色女人牲交| 久久精品国产99精品国产亚洲性色 | 成人三级黄色视频| 在线观看日韩欧美| 少妇 在线观看| 51午夜福利影视在线观看| 亚洲av片天天在线观看| 欧美黄色片欧美黄色片| 久久伊人香网站| 在线观看一区二区三区激情| 欧美日韩福利视频一区二区| 精品一区二区三区视频在线观看免费 | 欧美大码av| 天堂动漫精品| 91在线观看av| 啪啪无遮挡十八禁网站| 精品一区二区三区视频在线观看免费 | 人人妻人人添人人爽欧美一区卜| 色综合站精品国产| 搡老熟女国产l中国老女人| 午夜亚洲福利在线播放| 侵犯人妻中文字幕一二三四区| 欧美成狂野欧美在线观看| 欧美日韩亚洲高清精品| 欧美丝袜亚洲另类 | 中文字幕人妻丝袜制服| 亚洲午夜精品一区,二区,三区| 1024视频免费在线观看| 国产一区二区三区视频了| 黄色片一级片一级黄色片| 久久国产乱子伦精品免费另类| 日本撒尿小便嘘嘘汇集6| 日本欧美视频一区| 久久影院123| 长腿黑丝高跟| 香蕉久久夜色| 日韩av在线大香蕉| 一区二区三区激情视频| 日韩有码中文字幕| 免费看a级黄色片| 精品一区二区三区四区五区乱码| 午夜福利欧美成人| 淫妇啪啪啪对白视频| 国产免费现黄频在线看| 亚洲一区中文字幕在线| 久久九九热精品免费| 纯流量卡能插随身wifi吗| 亚洲欧美激情综合另类| 欧美精品啪啪一区二区三区| 满18在线观看网站| 日韩中文字幕欧美一区二区| 久久这里只有精品19| 精品久久久久久,| 黑人猛操日本美女一级片| 国产成年人精品一区二区 | av网站免费在线观看视频| 在线观看www视频免费| 美女 人体艺术 gogo| 国产三级在线视频| 国产高清videossex| 亚洲精品美女久久av网站| 中文字幕高清在线视频| 国产精品久久久久久人妻精品电影| 丰满饥渴人妻一区二区三| 热99re8久久精品国产| 国产在线观看jvid| 亚洲情色 制服丝袜| 国产成人精品在线电影| 757午夜福利合集在线观看| 高清毛片免费观看视频网站 | 如日韩欧美国产精品一区二区三区| 神马国产精品三级电影在线观看 | 欧美日本中文国产一区发布| 亚洲自偷自拍图片 自拍| 这个男人来自地球电影免费观看| 91字幕亚洲| 老司机福利观看| 国产精品免费一区二区三区在线| 亚洲av成人一区二区三| 俄罗斯特黄特色一大片| av免费在线观看网站| 亚洲一卡2卡3卡4卡5卡精品中文| av中文乱码字幕在线| 亚洲免费av在线视频| 午夜福利一区二区在线看| 久久人人爽av亚洲精品天堂| 国产精品av久久久久免费| 欧美精品亚洲一区二区| 日韩有码中文字幕| 男女下面进入的视频免费午夜 | 男女床上黄色一级片免费看| 搡老乐熟女国产| av欧美777| 亚洲一区高清亚洲精品| 三上悠亚av全集在线观看| 波多野结衣一区麻豆| 超碰97精品在线观看| 女警被强在线播放| 免费看a级黄色片| 人妻久久中文字幕网| 两个人免费观看高清视频| 久久热在线av| 亚洲成人国产一区在线观看| 久久青草综合色| 午夜福利免费观看在线| 在线国产一区二区在线| 中文字幕人妻丝袜一区二区| av网站在线播放免费| 国产又色又爽无遮挡免费看| www.精华液| 一进一出好大好爽视频| 久久久久精品国产欧美久久久| 最好的美女福利视频网| 亚洲免费av在线视频| 在线视频色国产色| 成人三级做爰电影| 日本 av在线| 午夜成年电影在线免费观看| 男女做爰动态图高潮gif福利片 | 国产麻豆69| 波多野结衣av一区二区av| 久久久久国产一级毛片高清牌| 日韩 欧美 亚洲 中文字幕| 日本三级黄在线观看| 91麻豆精品激情在线观看国产 | 男女床上黄色一级片免费看| 精品国内亚洲2022精品成人| videosex国产| 色播在线永久视频| 叶爱在线成人免费视频播放| 不卡av一区二区三区| 男女下面插进去视频免费观看| 水蜜桃什么品种好| 这个男人来自地球电影免费观看| 精品国产超薄肉色丝袜足j| 国产熟女午夜一区二区三区| 嫩草影视91久久| 桃色一区二区三区在线观看| 丁香欧美五月| 国产高清videossex| 欧美黑人欧美精品刺激| 丁香六月欧美| 丝袜美腿诱惑在线| 美女国产高潮福利片在线看| 男女下面插进去视频免费观看| 国产视频一区二区在线看| 久久精品亚洲av国产电影网| 少妇粗大呻吟视频| 两人在一起打扑克的视频| 精品一区二区三卡| www.熟女人妻精品国产| a级片在线免费高清观看视频| 怎么达到女性高潮| 一个人免费在线观看的高清视频| 一本大道久久a久久精品| 色精品久久人妻99蜜桃| 麻豆久久精品国产亚洲av | 亚洲美女黄片视频| 国产精品 欧美亚洲| 亚洲久久久国产精品| 91在线观看av| 欧美日韩av久久| www.www免费av| 黄色 视频免费看| 亚洲国产精品999在线| 91大片在线观看| 天天添夜夜摸| 一级黄色大片毛片| 19禁男女啪啪无遮挡网站| 丁香六月欧美| 十八禁网站免费在线| 亚洲av片天天在线观看| 日日干狠狠操夜夜爽| 国产精品1区2区在线观看.| 欧美日韩视频精品一区| 神马国产精品三级电影在线观看 | 精品熟女少妇八av免费久了| 18禁观看日本| 精品久久蜜臀av无| 亚洲成人国产一区在线观看| 日日摸夜夜添夜夜添小说| 欧美日韩亚洲综合一区二区三区_| 欧美国产精品va在线观看不卡| 母亲3免费完整高清在线观看| 国产亚洲av高清不卡| bbb黄色大片| 在线观看免费视频网站a站| 日本vs欧美在线观看视频| 国产免费av片在线观看野外av| 国产成人精品久久二区二区免费| av超薄肉色丝袜交足视频| 久久人人97超碰香蕉20202| 中文字幕色久视频| 国产精品一区二区三区四区久久 | 黄频高清免费视频| 国产无遮挡羞羞视频在线观看| 性少妇av在线| 亚洲成人国产一区在线观看| 亚洲欧美一区二区三区久久| 一级,二级,三级黄色视频| 亚洲精品国产区一区二| 女人被狂操c到高潮| 欧美老熟妇乱子伦牲交| 99国产精品99久久久久| 最近最新免费中文字幕在线|